Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700712 | 0.74 | L3MBTL1 (0.43) | L3MBTL1LPAR1LPAR3NMT1HIF1A | |
| SCHEMBL16700525 | 0.66 | ALOX5 (0.45) | L3MBTL1 | |
| SCHEMBL18227426 | 0.61 | NMT1 (0.47) | L3MBTL1NMT1HIF1ANPSR1RXFP1 | |
| SCHEMBL4009381 | 0.61 | ALOX5AP (0.43) | HIF1AMMP1MMP2MMP3MMP7 | |
| SCHEMBL1630077 | 0.60 | HIF1A (0.48) | L3MBTL1NMT1HIF1ANPSR1RXFP1 | |
| SCHEMBL23363075 | 0.59 | L3MBTL1 (0.38) | L3MBTL1NMT1 | |
| SCHEMBL27007666 | 0.58 | HSD11B1 (0.49) | L3MBTL1NMT1 | |
| SCHEMBL15329715 | 0.58 | NMT1 (0.40) | L3MBTL1NMT1MMP1MMP2MMP3 | |
| SCHEMBL11682083 | 0.57 | NPSR1 (0.54) | L3MBTL1NPSR1 | |
| SCHEMBL14711183 | 0.57 | LPAR1 (0.48) | L3MBTL1LPAR1LPAR3NPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321738-B2 | N-alkyltriazole compounds as LPAR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150133511-A1 | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133511-A1 | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | L3MBTL1 2346/4885LPAR1 1/4885LPAR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.